CLS Therapeutics is a New York City-based biopharmaceutical company focused on unlocking the full potential of an innovative anticancer gene therapy.
The company’s first-in-class lead candidate CLS-014 is a novel adeno-associated vector encoding recombinant DNase I enzyme designed to target cell-free DNA in serum with the high ability to fight cancers.
We are translating the new biology of cell-free DNA into novel therapeutic approaches to multiple cancers with unmet medical needs, beginning with our first program for pancreatic cancer.
CLS Therapeutics works to deliver on the promise of circulating nucleic acid science to advance new generation of transformative gene therapies for cancer patients.
We have built a team of internationally recognized experts in circulating nucleic acid science, gene therapy and oncology to develop and commercialize CLS-014 (Deoxynucleogene Ancparvovec) for the treatment of advanced or metastatic pancreatic adenocarcinoma.